Cargando…

A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

Although initial rituximab-containing chemotherapies achieve high response rates, indolent B-cell non-Hodgkin lymphoma (B-NHL), such as follicular lymphoma (FL), is still incurable. Therefore, new effective agents with novel mechanisms are anticipated. In this multicentre phase II study, patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ogura, Michinori, Ando, Kiyoshi, Suzuki, Tatsuya, Ishizawa, Kenichi, Oh, Sung Yong, Itoh, Kuniaki, Yamamoto, Kazuhito, Au, Wing Yan, Tien, Hwei-Fang, Matsuno, Yoshihiro, Terauchi, Takashi, Yamamoto, Keiko, Mori, Masahiko, Tanaka, Yoshinobu, Shimamoto, Takashi, Tobinai, Kensei, Kim, Won Seog
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Haematological Malignancy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282031/ https://www.ncbi.nlm.nih.gov/pubmed/24617454 http://dx.doi.org/10.1111/bjh.12819

Ejemplares similares

An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma
por: Andorsky, David J., et al.
Publicado: (2018)

Dose‐intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T‐cell leukaemia‐lymphoma: a randomized phase II study
por: Ishida, Takashi, et al.
Publicado: (2015)

SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study
por: Nordström, Lena, et al.
Publicado: (2014)

Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma
por: Arcaini, Luca, et al.
Publicado: (2017)

Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN)
por: Smith, Alexandra, et al.
Publicado: (2018)

Longer‐term follow‐up and outcome by tumour cell proliferation rate (Ki‐67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL‐001(EMERGE) pivotal trial
por: Goy, Andre, et al.
Publicado: (2015)

Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma
por: Zhao, Xiaoxian, et al.
Publicado: (2020)

p53 is associated with high‐risk and pinpoints TP53 missense mutations in mantle cell lymphoma
por: Rodrigues, Joana M., et al.
Publicado: (2020)

Aggressive, early resistant and relapsed mantle cell lymphoma distinct extrinsic microenvironment highlighted by transcriptome analysis
por: Le Bris, Yannick, et al.
Publicado: (2022)

Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R‐CHOP
por: Jeon, Young‐Woo, et al.
Publicado: (2019)

A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma
por: Watanabe, Takashi, et al.
Publicado: (2016)

The impact of SOCS1 mutations in diffuse large B‐cell lymphoma
por: Mellert, Kevin, et al.
Publicado: (2019)

Diagnostic markers for CNS lymphoma in blood and cerebrospinal fluid: a systematic review
por: van Westrhenen, Anouk, et al.
Publicado: (2018)

First‐line R‐CVP versus R‐CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4
por: Walewski, Jan, et al.
Publicado: (2019)

Early‐stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long‐term patient outcomes
por: Parsons, Susan K., et al.
Publicado: (2018)

Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom
por: Bröckelmann, Paul J., et al.
Publicado: (2018)

Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma
por: Holtan, Shernan G, et al.
Publicado: (2006)

Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine‐based high‐dose chemotherapy regimen
por: Musso, Maurizio, et al.
Publicado: (2015)

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
por: Feldman, Tatyana, et al.
Publicado: (2014)

A randomized, double‐blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma
por: Kubo, Kohmei, et al.
Publicado: (2016)

Peripheral T cell lymphoma, not otherwise specified (PTCL‐NOS). A new prognostic model developed by the International T cell Project Network
por: Federico, Massimo, et al.
Publicado: (2018)

Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma
por: Oflazoglu, Ezogelin, et al.
Publicado: (2008)

Combination lenalidomide‐rituximab immunotherapy activates anti‐tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma
por: Chiu, Hsiling, et al.
Publicado: (2019)

Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study
por: Pettengell, Ruth, et al.
Publicado: (2008)

Transformed mucosa‐associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction‐based clonality analysis
por: Kiesewetter, Barbara, et al.
Publicado: (2019)

Diagnosis of intravascular large B cell lymphoma: novel insights into clinicopathological features from 42 patients at a single institution over 20 years
por: Matsue, Kosei, et al.
Publicado: (2019)

Bortezomib maintenance after R‐CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial
por: Doorduijn, Jeanette K., et al.
Publicado: (2020)

Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma: post‐hoc analyses from a phase III trial
por: Pettengell, Ruth, et al.
Publicado: (2016)

Evaluation of the PIK3 pathway in peripheral T‐cell lymphoma and NK/T‐cell lymphoma
por: Huang, Dachuan, et al.
Publicado: (2020)

Lenalidomide plus rituximab (R(2)) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial
por: Becnel, Melody R., et al.
Publicado: (2019)

Clinical significance of TP53 mutations in adult T‐cell leukemia/lymphoma
por: Sakamoto, Yuma, et al.
Publicado: (2021)

A phase 1/2 trial of ublituximab, a novel anti‐CD20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab
por: Sawas, Ahmed, et al.
Publicado: (2017)

Clinical significance of CD28 gene‐related activating alterations in adult T‐cell leukaemia/lymphoma
por: Sakamoto, Yuma, et al.
Publicado: (2020)

Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high ‘life threat’ impact cardiopathy
por: Corazzelli, Gaetano, et al.
Publicado: (2011)

Indolent primary effusion lymphoma
por: Nagrale, Vidya, et al.
Publicado: (2020)

Application of the Euro Clonality next‐generation sequencing‐based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial
por: Genuardi, Elisa, et al.
Publicado: (2021)

Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma – A study from the Danish Lymphoma Registry
por: Andersen, Maja Dam, et al.
Publicado: (2022)

Lymphoplasmacytic lymphoma and marginal zone lymphoma involving bone marrow: A diagnostic dilemma. Useful clinicopathological features to accurate the diagnosis
por: García‐Abellás, Patricia, et al.
Publicado: (2022)

Atypical cytologic mantle cell lymphoma presentation
por: Chea, Mathias, et al.
Publicado: (2022)

Clinical characteristics and outcomes among 2347 patients aged ≥85 years with major lymphoma subtypes: a Nordic Lymphoma Group study
por: Wästerlid, Tove, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dgf6n6usbniflkkhirenbpknh0